Back to Search Start Over

Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study.

Authors :
Charleer, Sara
De Block, Christophe
Nobels, Frank
Radermecker, Régis P.
Lowyck, Ine
Mullens, Annelies
Scarnière, Denis
Spincemaille, Katrien
Strivay, Marie
Weber, Eric
Taes, Youri
Vercammen, Chris
Keymeulen, Bart
Mathieu, Chantal
Gillard, Pieter
RESCUE Trial Investigators
Source :
Diabetes Care; Dec2020, Vol. 43 Issue 12, p3016-3023, 8p
Publication Year :
2020

Abstract

<bold>Objective: </bold>In recent years, a growing number of people with type 1 diabetes gained access to real-time continuous glucose monitoring (rtCGM). Long-term benefits of rtCGM are unclear because of a lack of large studies of long duration. We evaluated whether real-world rtCGM use up to 24 months offered benefits, particularly in those living with impaired awareness of hypoglycemia (IAH).<bold>Research Design and Methods: </bold>This 24-month, prospective, observational cohort study followed 441 adults with insulin pumps receiving full reimbursement for rtCGM. Forty-two percent had IAH. The primary end point was evolution of HbA1c, with secondary end points change in acute hypoglycemia complications, diabetes-related work absenteeism, and quality of life scores. Additionally, we evaluated whether people could achieve glycemic consensus targets during follow-up.<bold>Results: </bold>After 24 months, HbA1c remained significantly lower compared with baseline (7.64% [60 mmol/mol] vs. 7.37% [57 mmol/mol], P < 0.0001). Sustained benefits were also observed for the score on the hypoglycemia fear survey and hypoglycemia-related acute complications irrespective of hypoglycemia awareness level. People with IAH had the strongest improvement, especially for severe hypoglycemia (862 events in the year before vs. 119 events per 100 patient-years in the 2nd year, P < 0.0001). Over 24 months, more people were able to meet hypoglycemia consensus targets at the expense of slightly fewer people achieving hyperglycemia consensus targets. Furthermore, the number of people with HbA1c <7% (<53 mmol/mol) without severe hypoglycemia events more than doubled (11.0% vs. 25.4%, P < 0.0001).<bold>Conclusions: </bold>Use of rtCGM led to sustained improvements in hypoglycemia-related glucose control over 24 months. Lower fear of hypoglycemia, fewer acute hypoglycemia-related events, and fewer diabetes-related days off from work were observed, particularly in those with IAH. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01495992
Volume :
43
Issue :
12
Database :
Complementary Index
Journal :
Diabetes Care
Publication Type :
Academic Journal
Accession number :
147097553
Full Text :
https://doi.org/10.2337/dc20-1531